Have you read these stories?

Has India stumbled upon a chance defence against coronavirus?

India's aversion to joining Asia’s sophisticated supply chain for production is what is saving it from virus.

National Pharmaceutical Pricing Authority

Feb 27, 2020, 11.04 PM IST



Stents price capping has improved its accessibility: Drug pricing regulator NPPA

According to the National Pharmaceutical Pricing Authority (NPPA) both stent manufactured and imported went up from 9.36 lakh in 2016 to 13.55 lakh in 2019. ”Indicating increased access because of price capping by NPPA. After a few revisions in last three years, a bare metal stent (BMS) is currently priced at Rs 8,261, and a drug eluting stent (DES) costs Rs 30,080.

NPPA tells chief secys to keep tabs on API availability

In a letter to the chief secretaries, the National Pharmaceutical Pricing Authority (...

8,700 pharma firms in India claimed tax deductions for ‘gifts’

Around 8,667 pharmaceutical companies claimed income tax deduction under “sale...

  • Unlike mature markets such as the US, where drug prices are market-controlled, here, the government and regulators play a pivotal role in the entire process. Regulators fix both the price companies pay for bulk drugs and the price at which they sell their products in the market, leaving little leeway to earn profit. For Indian pharma, this is a double-edged sword.

    Price regulation has also allowed better margins to Indian companies even as locally made, lower-priced products gain in the market, helping local players increase revenues. The share of Indian companies in terms of value has increased from 30% in 2016-17 to over 55% in 2019-20.

    The Department of Pharmaceuticals along with the Drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA) will discuss the issue of TMR with the stakeholders, in an effort to reduce prices of medicines & medical devices. The trade margin is the difference between the price at which the manufacturers/importers sell to stockists and the price charged to consumers.

    Meril Life’s first locally made biodegradable cardiac scaffold, a naturally dissolving stent, is known as MeRes100. The stent was approved by the Drug Controller General of India in 2017, when prices were cut, prompting Meril, based in Vapi, Gujarat, to hold back on launching the product.

    This is a departure from the existing mechanism in which all essential medicines automatically go under price control. The Standing National Committee will decide which medicines should be available in adequate numbers and assured quality.

    In a meeting held earlier this month with Niti Aayog, DoP also suggested that trade margin on all formulations and dosages be capped at 100%.

    Importers have opposed the decision to impose price caps on medical devices, arguing that the move will hurt innovation.

    As per survey, 50% of the respondents said that medical devices they came across, did not have MRPs.

    The list is intended to be the basis for policy action intended to prevent distributors, wholesalers, retailers and even hospitals from seeking exorbitant trade margins on products .

    The tough days were triggered primarily on account of several regulatory measures, including the cap on prices of stents and knee implants by the National Pharmaceutical Pricing Authority (NPPA), Icra said in a release.

    The ability to conduct clinical trials safely and transparently is crucial to developing new healthcare products.

    As per the new prices notified by the National Pharmaceutical Pricing Authority (NPPA), a bare metal stent (BMS) would now cost Rs 8,261, while the drug eluting stent (DES) will cost Rs 30,080.

Load More...

Other useful Links

Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service